Bentley Pharmaceuticals secured capacity at Cardinal Health’s new North Raleigh, NC-based facility for the scaleup and manufacture of clinical supplies of Bentley’s intranasal insulin product candidate.

The product candidate utilizes Bentley’s CPE-215® drug delivery technology to deliver insulin directly through diabetic patients’ nasal mucosa using a nasal spray.








This site uses Akismet to reduce spam. Learn how your comment data is processed.